PPT-Modeling Imatinib-Treated Chronic Myeloid Leukemia

Cara Peters cpeters3mathumdedu Advisor Dr Doron Levy dlevymathumdedu Department of Mathematics Center for Scientific Computing and Mathematical Modeling Introduction CML cancer of the blood. M. yeloid Leukemia. Amer Rassam, M.D.. Learning Objectives. Myeloproliferative. disorders (MPDs). Molecular . genetics of chronic myeloid . leukemia. Clinical manifestations and diagnosis of chronic myeloid leukemia. and. Breast Cancer Conference. CML . ASH Update. Michael J. Mauro, MD. CML Abstracts. Novel Agents. Abstract # 109. : . A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib or with the T315I Mutation. MPD. Myeloproliferative. . neoplasms. (MPN) constitute one of five categories of myeloid malignancies, according to the World Health Organization (WHO) classification system for hematopoietic . tumors. Rebecca L. King, . Gerald Wertheim, Michele E. Paessler. The Children’s Hospital of Philadelphia. Perelman School of Medicine at the University of Pennsylvania. Philadelphia, PA. Clinical History. 13 year old boy. Amer Rassam, M.D.. Learning Objectives. Myeloproliferative. disorders (MPDs). Molecular . genetics of chronic myeloid . leukemia. Clinical manifestations and diagnosis of chronic myeloid leukemia. Overview of the treatment of chronic myeloid leukemia. oncoproteins. that block differentiation and promote proliferation of immature cells. The Myeloid Lymphoid Leukemia gene (. MLL. ) is frequently involved in these translocations, and is considered a driver of the AML. Differentiation promoting drugs, such as all-trans-retinoic acid (ATRA) are an attractive alternative to cytotoxic chemotherapy, but few types of AML, other than acute . PROGNOSTIC FACTORS. Although the first published reports of leukemia occurred in 1845 by Bennett and Virchow, the lack of refined diagnostic methodology limited the distinction between myeloid and lymphoid acute leukemia, With the development of refined staining techniques, followed by microscopy and histochemical staining by the mid-20th century, this distinction was . BSW00073 / OK 11 - ONC - 152 1 July , 2011 Fact Sheet Leukemia is a cancer that begins in the bone marrow ( the soft inner part of some bones), but in most cases, moves into the blood. It can t hen s 1 Chronic myeloid leukemia Description Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone erythrocyteserythrocytes leukocytesleukocytes( thrombocytes) that are involv neoplasms. Uncontrolled . proliferation and . decreased apoptotic . activity with variable degrees of differentiation . Composed of relatively mature . cells. Indolent. . (. If . untreated, the course is in months . Sofia Kolovich. 1. , Allison LaRocco. 1. , . Malith. Karunasiri. 1. , Girish Rajgolikar. 1. , Allison Walker. 1. , Ramiro Garzon. 1. , Marius Bill. 1. , Adrienne Dorrance. 1. . 1. The Ohio State University Comprehensive Cancer Center, Division of Hematology, The Ohio State University, Columbus, OH 43210.. Goals. Incidence. Etiology. Diagnosis. Types/Classification. Treatment. Primary Care Pearls. Incidence. 30% of all cancers in childhood. Peak incidence 2-5 years of age. males > females. Caucasian > African American. CONSULTANT HAEMATOLOGIST . HEAD OF HAEMATOLOGY DIVISION. DEPARTMENT OF PATHOLOGY. Heterogeneous group of hematopoietic . neoplasms. Uncontrolled . proliferation and . decreased apoptotic . activity with variable degrees of differentiation . Jayllex Mills,. PharmD Candidate. AML Background. Hematologic malignancy affecting the blood and bone marrow. Result of proliferation of abnormal myeloid stem cell derivatives and interference of normal blood cell production.